title: Rho inhibitor prevents ischemia-reperfusion injury in rat steatotic liver.
abstract: OBJECTIVE
  Hepatic stellate cells are thought to play a role in modulating intrahepatic vascular resistance based on their capacity to contract via Rho signaling. We investigated the effect of a Rho-kinase inhibitor on ischemia-reperfusion injury in the steatotic liver.
  
  
  METHODS
  Steatotic livers, induced by a choline-deficient diet in rats, were subjected to ischemia-reperfusion injury. Hepatic stellate cells isolated from steatotic livers were analyzed for contractility and Rho signaling activity. The portal pressure of the perfused rat liver and the survival rate after ischemia-reperfusion were also investigated.
  
  
  RESULTS
  Hepatic stellate cells from steatotic livers showed increased contractility and upregulation of Rho-kinase 2 compared with those from normal livers. Furthermore, endothelin-1 significantly enhanced the contractility and phosphorylation level of myosin light chain and cofilin in hepatic stellate cells isolated from steatotic livers. A specific Rho-kinase inhibitor, fasudil, significantly suppressed the contractility and decreased the phosphorylation levels of myosin light chain and cofilin. Serum levels of endothelin-1 were markedly increased after IR in rats with steatotic livers, whereas fasudil significantly decreased endothelin-1 serum levels. Rats with steatotic livers showed a significant increase in portal perfusion pressure after ischemia-reperfusion and a significant decrease in survival rate; fasudil treatment significantly reduced these effects.
  
  
  CONCLUSIONS
  Activation of Rho/Rho-kinase signaling in hepatic stellate cells isolated from steatotic livers is associated with an increased susceptibility to ischemia-reperfusion injury. A Rho-kinase inhibitor attenuated the activation of hepatic stellate cells isolated from steatotic livers and improved ischemia-reperfusion injury in steatotic rats.
authors.affiliation: Department of Surgery, Division of Frontier Medical Science, Programs for Biomedical Research, Graduate School of Biomedical Sciences, Hiroshima University, Hiroshima, Japan.
authors.forename: Shintaro
authors.initials: S
authors.lastname: Kuroda
authors.forename: Hirotaka
authors.initials: H
authors.lastname: Tashiro
authors.forename: Yuka
authors.initials: Y
authors.lastname: Igarashi
authors.forename: Yoshisato
authors.initials: Y
authors.lastname: Tanimoto
authors.forename: Junko
authors.initials: J
authors.lastname: Nambu
authors.forename: Akihiko
authors.initials: A
authors.lastname: Oshita
authors.forename: Tsuyoshi
authors.initials: T
authors.lastname: Kobayashi
authors.forename: Hironobu
authors.initials: H
authors.lastname: Amano
authors.forename: Yuka
authors.initials: Y
authors.lastname: Tanaka
authors.forename: Hideki
authors.initials: H
authors.lastname: Ohdan
mesh_terms: D019307:1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine / Q000031:analogs & derivatives / Q000494:pharmacology; D051339:Actin Depolymerizing Factors / Q000378:metabolism; D000818:Animals; D019332:Endothelin-1 / Q000097:blood; D005234:Fatty Liver / Q000150:complications / Q000188:drug therapy* / Q000201:enzymology* / Q000473:pathology; D055166:Hepatic Stellate Cells / Q000187:drug effects / Q000201:enzymology / Q000473:pathology; D008099:Liver / Q000187:drug effects / Q000201:enzymology* / Q000293:injuries*; D008297:Male; D018994:Myosin Light Chains / Q000378:metabolism; D010766:Phosphorylation; D047428:Protein Kinase Inhibitors / Q000494:pharmacology; D051381:Rats; D017208:Rats, Wistar; D015427:Reperfusion Injury / Q000201:enzymology / Q000209:etiology / Q000517:prevention & control*; D054460:rho-Associated Kinases / Q000037:antagonists & inhibitors*
chemical_list: D051339:Actin Depolymerizing Factors; D019332:Endothelin-1; D018994:Myosin Light Chains; D047428:Protein Kinase Inhibitors; D019307:1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; D054460:rho-Associated Kinases; C049347:fasudil